The impact of binge eating behavior on lithium- and quetiapine-associated changes in body weight, body mass index, and waist circumference during 6 months of treatment: Findings from the bipolar CHOICE study.
The impact of binge eating behavior on lithium- and quetiapine-associated changes in body weight, body mass index, and waist circumference during 6 months of treatment: Findings from the bipolar CHOICE study.
复制标题
治疗 6 个月期间暴食行为对锂和喹硫平相关的体重、体重指数和腰围变化的影响：双相 CHOICE 研究的结果。
DOI：
10.1016/j.jad.2018.09.025
复制
发表时间：
2020
影响因子：
6.6
通讯作者：
Thase,
中科院分区：
文献类型：
--
作者：
Yaramala,SatyanarayanaR;McElroy,SusanL;Geske,Jennifer;Winham,Stacey;Gao,Keming;Reilly-Harrington,NoreenA;Ketter,TerenceA;Deckersbach,Thilo;Kinrys,Gustavo;Kamali,Masoud;Sylvia,LouisaG;McInnis,MelvinG;Friedman,EdwardS;Thase,
背景锂和喹硫唑啉可导致体重增加，但其比较长期的人体测量效果是未知的，基线暴饮暴食（BE）行为的潜在调节作用也是未知的。482名患有DSM-IV双相情感障碍的成年人参加了一项锂和奎替利的比较有效性研究，双极选择（Bipolar CHOICE）。在基线和第2、4、6、8、12、16、20和24周时进行人体测量。BE行为定义为基线时对MINI项目M1和M3的肯定反应。数据进行了分析，使用混合模型重复测量的方法，调整基线值的依赖measurement.ResultsOn平均，体重和BMI增加超过6个月的锂和quetioline。然而，用奎替鲁肽治疗的那些经历了体重从基线的更大增加（峰值变化，+3.6 lbs。vs. + 1.4 lbs.）和BMI（峰值变化，+ 0.6 kg/m2 vs. + 0.3 kg/m2），从2周开始（组x时间，F8，3052= 2.9，体重p = 0.003，F8，3052= 3.0，BMI p = 0.002）。仅在奎替利组中观察到腰围显著增加。药物治疗与体重（组x时间x暴饮暴食状态，F1，2770= 2.0，p = 0.002）、BMI（F1，2767= 2.0，p = 0.002）和腰围（仅女性，F25，1621= 2.9，p < 0.0001）变化之间的关系受到BE行为的调节。体重和BMI以及女性腰围在24周内的最大增加发生在基线暴饮暴食的奎硫平治疗患者中，相对于奎硫平治疗患者没有暴饮暴食以及锂治疗患者有或没有基线暴饮暴食。在6个月的治疗中，奎替鲁肽与锂基治疗相比，腰围发生了变化。研究药物对这些人体测量指标的影响受到基线时BE行为的调节。
BackgroundLithium and quetiapine can cause weight gain, but their comparative longer term anthropometric effects are unknown, as are the potential moderating effects of baseline binge-eating (BE) behavior.MethodsWe assessed 6 month changes in body weight, body mass index (BMI) and waist circumference in 482 adults with DSM-IV bipolar disorders who participated in a comparative effectiveness study of lithium and quetiapine with evidence-based adjunctive treatment (Bipolar CHOICE). Anthropometric measurements were obtained at baseline, and at 2, 4, 6, 8, 12, 16, 20, and 24 weeks. BE behavior was defined as affirmative responses to MINI items M1 and M3 at baseline. Data were analyzed using a mixed model repeated measures approach, adjusted for baseline values of dependent measures.ResultsOn average, body weight and BMI increased over 6 months with lithium and quetiapine. However, those treated with quetiapine experienced greater increases from baseline in body weight (peak change, + 3.6 lbs. vs. + 1.4 lbs.) and BMI (peak change, + 0.6 kg/m2vs. + 0.3 kg/m2), starting at 2 weeks (group x time, F8,3052= 2.9, p = 0.003 for body weight, F8,3052= 3.0, p = 0.002 for BMI). Significant increases in waist circumference were observed only with quetiapine. The relationship between drug treatment and changes in body weight (group x time x binge eating status, F1,2770= 2.0, p = 0.002), BMI (F1,2767= 2.0, p = 0.002), and waist circumference (women only, F25,1621= 2.9, p < 0.0001) were moderated by BE behavior. The largest increases over 24 weeks in body weight and BMI, and waist circumference in women, occurred for quetiapine-treated patients with baseline binge-eating, relative to quetiapine-treated patients without binge eating and lithium-treated patients with or without baseline binge-eating.LimitationsBipolar CHOICE was not designed to study anthropometric outcomes.ConclusionsGreater changes in body weight, BMI, and waist circumference occurred with quetiapine- versus lithium-based treatment over 6 months of treatment. The effects of study drugs on these anthropometric measures were moderated by BE behavior at baseline.